Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

This long-term follow-up analysis evaluated overall survival (OS) and relapse-free survival (RFS) in a phase 2 study of the bispecific T-cell engager antibody construct blinatumomab in 36 adults with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). In the primary analysis, 25 (69%...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Zugmaier, Gerhard, Gökbuget, Nicola, Klinger, Matthias, Viardot, Andreas, Stelljes, Matthias, Neumann, Svenja, Horst, Heinz-A., Marks, Reinhard, Faul, Christoph, Diedrich, Helmut, Reichle, Albrecht, Brüggemann, Monika, Holland, Chris, Schmidt, Margit, Einsele, Hermann, Bargou, Ralf C., Topp, Max S.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2015
Témata:
Lymphoid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4671107/
https://ncbi.nlm.nih.gov/pubmed/26480933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-06-649111
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky